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Acute myeloid leukemia (AML) is maintained by self-renewing leukemic stem
cells (LSCs). A fundamental problem in treating AML is that conventional
therapy fails to eliminate LSCs, which can reinitiate leukemia. Heat shock
transcription factor 1 (HSF1), a central regulator of the stress response, has
emerged as an important target in cancer therapy. Using genetic Hsf1 deletion
and a direct HSF1 small molecule inhibitor, we show that HSF1 is speciﬁcally
required for the maintenance of AML, while sparing steady-state and stressed
hematopoiesis. Mechanistically, deletion of Hsf1 dysregulates multifaceted
genes involved in LSC stemness and suppresses mitochondrial oxidative
phosphorylation through downregulation of succinate dehydrogenase C
(SDHC), a direct HSF1 target. Forced expression of SDHC largely restores the
Hsf1 ablation-induced AML developmental defect. Importantly, the growth
and engraftment of human AML cells are suppressed by HSF1 inhibition.
Our data provide a rationale for developing efﬁcacious small molecules to
speciﬁcally target HSF1 in AML.
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Acute myeloid leukemia (AML) is the most common acute leukemia in
adults and occurs increasingly with age with devastating outcomes1–3.
Although increasingly reﬁned knowledge of AML biology has led to the
development of new targeted agents, such as FLT3, BCL2 or IDH inhibitors, current treatment for most patients still largely relies on standard “7 + 3” chemotherapy and allogeneic stem cell transplantation2.
The WHO classiﬁcation divides AML into distinct categories based on
recurrent cytogenetic abnormalities, molecular mutations, morphology, and immunophenotypic features. The aberrant leukemia blast

proliferation and the stalling of blast differentiation are common features of AML. Regardless of the subtype, all AML is initiated and
maintained by small numbers of self-renewing leukemic stem cells
(LSCs)4–7. A fundamental problem in treating leukemia is that conventional therapy can destroy the bulk of leukemia blasts, but fails to
eliminate the LSCs, which can change status and reinitiate malignancy
after a period of latency8,9. Thus, there is an urgent need to identify
and target key molecules that speciﬁcally regulate the self-renewal of
AML stem cells.
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AML stem cells are self-renewing quiescent blasts. Depending on
the subtype, some LSCs are positive for CD34, like its normal counterpart, but others, for example, AML with NPM1 mutations and AML
with monocytic differentiation, are negative for CD34. As there is no
general surface marker for LSCs, AML stem cells have recently been
enriched through their low reactive oxygen species (ROS) production
status compared with the bulk blasts10. Increasing evidence has shown
that AML stem cells have higher mitochondrial mass than normal
hematopoietic stem/progenitor cells (HSPCs). They also have unique
mitochondrial characteristics with increased mitochondrial biogenesis
that differs from most other cancers in that they are primarily
dependent on mitochondrial oxidative phosphorylation (OXPHOS),
not glycolysis, to generate ATP for survival9–11. Consistent with these
observations, blocking mitochondrial oxidative phosphorylation is
selectively cytotoxic to AML stem cells9,11–16.
Heat shock transcription factor 1 (HSF1) upregulates the expression
of heat shock proteins (HSPs) and thus protects cells from misfolded
protein-induced proteotoxic stress17–19. Recent genome-wide studies
revealed that HSF1 reprograms the transcription of genes involved in a
multitude of processes, including metabolism, gametogenesis, aging,
and cancer. The expression, activity, and nuclear localization of HSF1 are
generally elevated in cancers in response to the increased biosynthetic
demands and oncogenic stresses resulting from rapid cell proliferation
and the mutant cancer proteome18,20–23. HSF1 plays a fundamental role in
cancer biology since deletion of the Hsf1 gene, or reduction in HSF1
expression, markedly reduces growth, survival, and metastatic potential
through the regulation of signal transduction, transcription, translation,
apoptosis, mitochondrial metabolism, and ROS clearance in a range of
solid tumors18,24–26. Although HSF1 is not an oncogene, it enables cancer
cells to accommodate imbalances in signaling and alterations in DNA,
protein, and energy metabolism, a phenomenon called “non-oncogene
addiction”18,24,27–29.
Emerging evidence supports the involvement of HSF1 in malignant hematopoiesis. Hsf1 is transcriptionally upregulated by
NOTCH1 signaling in T cell acute lymphoblastic leukemia (T-ALL), and
conditional, cancer cell-speciﬁc Hsf1 ablation suppressed cell growth
using a mouse T-ALL model and human T-ALL cell lines30. Although the
role of HSF1 in solid cancers has been well characterized and is
emerging in leukemia30–32, to date, few studies have been conducted to
speciﬁcally evaluate the role and mechanism of action of HSF1 in AML
stem cells33. Using systemic and conditional Hsf1 knockout mice, as
well as pharmacological inhibition, we show that HSF1 is speciﬁcally
required for the maintenance of function of both murine and human
AML stem cells, while being dispensable for normal steady-state and
stressed hematopoiesis. Furthermore, our data suggest that nuclear
HSF1 levels may be used as a clinical marker to monitor AML status.
Together, these observations strongly support the development of
HSF1 inhibitors to target LSC self-renewal for the treatment of patients
with AML.

Results
HSF1 Is Required for the maintenance of MLL-AF9–induced AML
Given the critical role of HSF1 in solid cancers and its emerging role in
leukemia30–32,34, we investigated the role of HSF1 in AML using conditional Hsf1 deletion mice in combination with the well-established
MLL-AF9–induced AML mouse model35,36. We ﬁrst deleted Hsf1 in
hematopoietic cells by crossing Hsf1ﬂ/ﬂ mice37 with Vav-cre mice
(hereafter Hsf1KO, Supplementary Fig. 1a). In the absence of Hsf1, the
development of MLL-AF9 leukemia in vivo was signiﬁcantly delayed
(Fig. 1a), suggesting that HSF1 is required for the initiation of MLLAF9–induced AML. To investigate if HSF1 is required for the maintenance of full-blown AML, which is more important when considering
AML patient treatment, we generated conditional Hsf1 knockout mice
by crossing Hsf1ﬂ/ﬂ mice with ROSA26-CreERT2 mice (hereafter Hsf1ﬂ/
ﬂ
creER). We ﬁrst established MLL-AF9−immortalized colony-forming
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cells through serial plating of MLL-AF9–transduced HSPCs (Lin–cKit+
Sca1+) from Hsf1ﬂ/ﬂcreER or Hsf1+/+creER or Hsf1ﬂ/ﬂ mice. After 4 rounds
of serial plating, the MLL-AF9–transformed cells grew in liquid medium in the presence of IL-3 (10 ng/mL) (Fig. 1b). We then plated equal
numbers of transformed cells in methylcellulose media in the presence
or absence of 4-hydroxytamoxifen (4-OHT) to induce Hsf1 deletion
(Supplementary Fig. 1b). Compared with controls, 4-OHT−induced
deletion of HSF1 signiﬁcantly reduced cell growth and colony formation (Fig. 1c, d). Importantly, the reduced colony-forming ability of 4OHT−treated leukemia cells lasted after withdrawal of 4-OHT (Fig. 1e).
We transplanted MLL-AF9–transduced HSPCs from Hsf1+/+creER or
ﬂ/ﬂ
Hsf1 creER mice into lethally irradiated recipients along with radioprotective/rescue cells. Five weeks later, recipient mice were started
on tamoxifen (Tam) treatment by oral gavage (Fig. 1f). Mice that
received MLL-AF9–transduced Hsf1+/+creER cells (treated with Tam), or
Hsf1ﬂ/ﬂcreER cells (vehicle only) developed AML within 3 months.
However, the progression of AML in recipient mice receiving MLLAF9–transduced Hsf1ﬂ/ﬂcreER cells and treated with Tam was signiﬁcantly delayed (Fig. 1g). We conﬁrmed that Tamoxifen treatment
efﬁciently deleted Hsf1 at the genomic level and drove a strong reduction in HSF1 protein abundance (Supplementary Fig. 1c, d). The LSCs in
MLL-AF9-induced AML have been deﬁned as lineage marker-negative,
cKit-positive, Sca1-negative, CD16-positive, and CD34-positive (deﬁned
as lin−ckit+Sca1−CD16+CD34+) granulocyte-macrophage progenitor-like
cells35. Analysis of mice with fully developed leukemia showed that
acute Hsf1 ablation reduced the LSC frequencies and increased the
frequencies of CD11b+ more mature and differentiated leukemia cells.
This indicates that HSF1 maintains LSC homeostasis and loss of Hsf1
accelerates LSC differentiation (Fig. 1h–j). Importantly, when FACSsorted LSCs from Tam-treated or vehicle-treated (Con) leukemic mice
were transplanted into the secondary sublethally irradiated CD45.1
recipients, the repopulating ability of Tam-treated leukemia cells was
signiﬁcantly reduced (Fig. 1k). In addition, when we treated primary
recipient mice twice with Tam (with a 10-day interval), no primary and
secondary recipient mice developed AML (Fig. 1l, Supplementary
Fig. 1e), indicating that Hsf1 ablation strongly impairs LSC self-renewal
capacity. Collectively, these results indicate that HSF1 is required for
both the initiation and maintenance of MLL-AF9–induced AML.

HSF1 is dispensable for steady-state and stressed hematopoiesis
The ideal AML targeting therapy would be speciﬁc to AML stem cells,
while sparing normal HSPCs. HSPCs are constantly exposed to various
physiopathologic stresses, e.g., inﬂammation, infection, therapeutic
drugs, hypoxia, and irradiation. Given the critical role of HSF1 in the
maintenance of normal cellular homeostasis and stress resistance in
general, we investigated if deletion of Hsf1 adversely affects normal
hematopoiesis using Hsf1ﬂ/ﬂVav-cre mice. Interestingly, deletion of Hsf1
in all hematopoietic cells had no signiﬁcant impact on the whole bone
marrow (BM) numbers (Supplementary Fig. 2a), lineage distribution
(Supplementary Fig. 2b), or the frequencies and absolute numbers of
long- and short-term HSCs (Supplementary Fig. 2c, d). In addition,
there were no differences in the frequencies of CMP (common myeloid
progenitor), GMP (granulocyte-monocyte progenitor), MEP (megakaryocyte-erythrocyte progenitor), and CLP (common lymphoid progenitor) between control and Hsf1KO mice (Supplementary Fig. 2e).
As HSF1 is an important regulator of stress responses, we asked if
HSF1 is required for stressed hematopoiesis. One exogenous stress
frequently used in HSC studies is the treatment of mice with the cell
cycle−speciﬁc myelotoxic drug, 5-ﬂuorouracil (5-FU). However, we
found no differences in survival between Hsf1KO and control mice to
repeated 5-FU challenges (i.p. 150 mg/kg, on day 0, 7, and 14) (Fig. 2a).
In addition, there was no difference in BM HSC number or frequency
after sublethal radiation (Fig. 2b) or lipopolysaccharide stimulation
(Fig. 2c), two mechanistically distinct stresses compared with 5-FU
treatment. BM transplantation, especially serial BM transplantation is
2
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Fig. 1 | HSF1 is required for the initiation and maintenance of MLL-AF9–induced
AML. a Survival curve of mice receiving MLL-AF9 transduced LSK (Lin–cKit+Sca1+)
cells from Hsf1ﬂ/ﬂ (Con) or Hsf1ﬂ/ﬂVav-Cre + (Hsf1KO) mice (n = 5 mice/group). Logrank test, *p = 0.0021. b Scheme of serial plating for establishing immortalized
leukemia cells. c MLL-AF9 Hsf1ﬂ/ﬂcreER leukemia cell numbers in the presence or
absence (vehicle, Con) of 4-hydroxytamoxifen (the active metabolite of tamoxifen, 4-OHT, 200 nM). 1 × 103 leukemia cells were plated and counted 3–4 days
later (n = 6 independent replicates). *p = 2.5 × 10−5. d Colony numbers formed in
the presence or absence of 4-OHT (n = 8 independent replicates). *p = 7.3 × 10−6.
e 500 cells from vehicle (Con) or 4-OHT treated colony assay (d) were replated
without further 4-OHT treatment (n = 6 independent replicates). *p = 4.24 × 10−7.
f Scheme of establishment of MLL-AF9–induced AML and delivery of tamoxifen
to induce Hsf1 deletion. g Survival curve of mice receiving MLL-AF9–transduced
LSK cells from Hsf1+/+creER or Hsf1ﬂ/ﬂcreER mice with or without Tam treatment

(n = 8 mice/group). Log-rank test, *p = 0.0002. h Frequencies of LSCs in MLL-AF9
Hsf1ﬂ/ﬂcreER leukemic mice with or without Tam treatment (n = 4 independent
replicates). *p = 2.2 × 10−5, **p = 0.017. i Frequencies of CD11b+ leukemia cells in
MLL-AF9 Hsf1ﬂ/ﬂcreER leukemic mice with or without Tam treatment (n = 3 independent replicates). *p = 2.79 × 10−5. In (c–e, h, i), two-tailed t test was used, data
are presented as mean values ± SEM. j Wright-Giemsa staining of LSC-derived
colony forming cells with or without 4-OHT treatment (n = 3 independent replicates). Note that Tam treatment induced LSC differentiation with reduced
nuclear to cytoplasmic ratio. Scale bar, 5 μM. k Survival curve of mice receiving
LSCs from full-blown MLL-AF9 Hsf1ﬂ/ﬂcreER leukemic mice treated with or without
Tam (n = 5 mice/group). Log-rank test, *p = 0.0019. l Survival curve of mice
receiving LSCs from full-blown MLL-AF9 Hsf1ﬂ/ﬂcreER leukemic mice treated with
two cycles of Tam (n = 5 mice/group). Log-rank test, *p = 0.0031. Source data are
provided as a Source Data ﬁle.

the gold standard and most rigorous way to test HSC self-renewal
in vivo. Thus, we carried out serial BM transplantation to evaluate HSC
self-renewal and multi-lineage differentiation potential in vivo. However, no signiﬁcant differences in donor chimerisms or lineage commitment were detected, even after tertiary transplantation (Fig. 2d, e).
In addition, we found there were no signiﬁcant impacts in donor chimerisms when Hsf1 was acutely ablated in adult hematopoiesis by Tam
treatment (Supplementary Fig. 2f, g). Collectively, these data and the
two recent reports38,39 demonstrate that HSF1 is not required for either
steady-state or stressed hematopoiesis.

dependent, transcription-independent roles40–42. HSF1 contains the
highly conserved N-terminal DNA-binding domain (DBD), hydrophobic heptad repeats (HR-A, HR-B and HR-C), and the C-terminal
transactivation domain, which is necessary for the transcription of
target genes43,44. In addition, the regulatory domain (RD), located
between the HR-A/B and HR-C domains, is responsible for suppressing
HSF1 activity under non-stress conditions (Fig. 3a)17,45. To test if HSF1
DNA binding is required for the maintenance of LSC self-renewal, we
retrovirally transduced wild-type HSF1, a constitutively active (ΔRDT,
deletion of RD along with substitution of a hydrophobic amino acid in
the HR-C) mutant, and an inactive (R71G, cannot bind to promoter heat
shock elements) mutant HSF146 into MLL-AF9-expressing Hsf1ﬂ/ﬂcreER
cells and treated them with or without 4-OHT to excise the endogenous Hsf1 gene. The wild type and mutant HSF1 protein expression were
documented by Western blotting (Fig. 3b). Impaired colony formation

HSF1 DNA binding is required for the regulation of LSC selfrenewal
Classically, the multifaceted functions of HSF1 have been ascribed to
its impact on transcriptional regulation. However, HSF1 has context-
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Fig. 2 | HSF1 is dispensable for stressed hematopoiesis. a Kaplan–Meier survival
curves of Hsf1ﬂ/ﬂ (Control, Con) or Hsf1ﬂ/ﬂVav-Cre+ (Hsf1KO) mice treated with
weekly doses of 5-FU (150 mg/kg, IP, Con n = 7 mice; Hsf1KO, n = 6 mice). b HSC
(deﬁned as Lin−cKit+Sca1+CD150+ CD48−) numbers of Con or Hsf1KO mice at different time points after sublethal (6.5 Gy) radiation (Con, n = 3 mice at each time
points, Hsf1KO, n = 3 mice at Day 0 and 10, n = 5 mice at Day 30 and n = 4 at Day 45).
c Percentages of HSCs in Con or Hsf1KO mice (3 mice/group) treated with 35 μg of
LPS twice (48 h apart) and analyzed 24 h after the second injection. d Donor

chimerisms of mice serially transplanted with control (Con) or Hsf1KO HSCs (primary, 500 cells/mouse, secondary and tertiary BMT, 2 × 106 BM cells from primary
or secondary recipients. e Frequencies of CD3+ T cells, B220+ B cells, Mac1+Gr1−
monocytes and Mac1+Gr1+ granulocytes in primary, secondary, and tertiary recipient mice transplanted with Con or Hsf1KO KLS cells. d, e n = 4/group for primary
and secondary BMT, and n = 5/group for tertiary BMT. In (b–e), data are presented
as mean values ± SEM. Source data are provided as a Source Data ﬁle.

observed for MLL-AF9-expressing Hsf1ﬂ/ﬂcreER cells in the presence of
4-OHT was partially restored with wild-type HSF1, nearly fully restored
with the constitutively active HSF1-ΔRDT mutant and was not
improved by expression of the HSF1 R71G mutant that has defective
DNA binding (Fig. 3c). These results demonstrate that the DNA binding
activity of HSF1 is required for the maintenance of LSC self-renewal and
imply that proper HSF1-regulated gene expression, rather than a
transcription-independent role, is critical for LSC self-renewal.

genes related to LSC stemness: Cd34, Flt3 and Bcat1 (Fig. 4b). The
upregulation of cell cycle inhibitors Cdkn1a and Cdkn1c, suggested
that deletion of Hsf1 affects cell proliferation (Fig. 4b). Importantly,
Hsf1 ablation downregulated genes related to oxidative phosphorylation (OXPHOS) (Fig. 4c). We also applied Gene Set Enrichment Analysis
(GSEA) to identify pathways differentially regulated by Hsf1 ablation
and found that in the absence of Hsf1, genes involved in regulating
stemness (increased expression of genes that are downregulated in
HSCs) (Fig. 4d), OXPHOS (Fig. 4e) and tricarboxylic acid (TCA) cycle
(Fig. 4f) were downregulated. These data prompted us to further
investigate if HSF1 directly regulates genes involved in mitochondrial
metabolism. To this end, we performed CUT&RUN (Cleavage Under
Targets & Release Using Nuclease) using sort-puriﬁed LSCs. Interestingly, peak call enrichment demonstrated that HSF1-bound genes in
LSCs are mainly involved in metabolism, OXPHOS and protein folding
(Fig. 4g), consistent with the above RNA-seq results. We focused on
one of the direct HSF1 target genes, Sdhc, which together with Sdha,
regulates OXPHOS activity through the electron transport complex II
(Fig. 4h, and see below). Collectively, these data suggest that in LSCs,
HSF1 regulates a diverse functional array of genes, including mitochondrial metabolism, in addition to its classic role in the heat shock
response.

Hsf1 ablation impairs LSPC proliferation and increases LSPC
apoptosis
To evaluate the basis for the dependency of LSPCs (leukemia stem/
progenitor cells, deﬁned as CD11b+cKithigh+ AML cells47) on HSF1, we
examined the impact of Hsf1 deletion on LSPC proliferation, apoptosis,
and protein synthesis. Hsf1 deletion suppressed EdU incorporation (a
marker of proliferation) with decreased percentages of LSPCs at S
phase and increased percentages of LSPCs at G0/G1 phase compared
to control LSPCs (Fig. 3d). In addition, Hsf1 ablation strongly increased
LSPC apoptosis as measured by the elevation in Annexin V and caspase
3 (Fig. 3e, f). As protein translation has been linked to HSF1 function26,
we detected modest, but signiﬁcantly impaired protein synthesis in the
absence of Hsf1 (Fig. 3g).

Hsf1 ablation dysregulates genes involved in multifaceted
functions of LSCs
Since our data demonstrate that HSF1 DNA binding is important for
LSC self-renewal, we performed RNA-sequencing (RNA-seq, deposited
and Source Data) to investigate the underlying molecular mechanisms
whereby ablation of Hsf1 suppresses AML development using FACS
sorted Hsf1KO or control LSCs. Consistent with HSF1 being a critical
regulator of HSPs, the expression of Hsp90, Hspa1a, Hspa1b, Hspd1,
Hspe1, Hspa4, and Hspa8 was signiﬁcantly reduced in Hsf1KO LSCs
compared with control LSCs (Fig. 4a). In addition, consistent with the
enhanced LSC differentiation and loss of LSC stemness observed in the
absence of Hsf1, RNA-seq revealed that deletion of Hsf1 upregulated
the expression of genes related to myeloid differentiation: Itgam/
Cd11b, Mpo, Elane, and Csf1, and downregulated the expression of
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HSF1 is a key regulator of oxidative phosphorylation in AML
The above data, that Hsf1 ablation dysregulates genes involved in
OXPHOS, prompted us to further investigate the impact of Hsf1
ablation on AML metabolism, given the fact that AML LSCs are primarily dependent on mitochondrial OXPHOS to generate ATP for
survival11,48,49. It has been shown that MLL-AF9−induced AML relies on
intact glucose metabolism, that LSCs utilize glucose through
OXPHOS50,51, and HSF1 provides sustained glucose uptake by tumor
cells24. We tested glucose uptake in the presence or absence of Hsf1 in
Hsf1ﬂ/ﬂcreER LSPCs. However, we found that Hsf1 ablation had no
impact on LSPC glucose uptake, as evaluated by 2-NBDG incorporation (Fig. 5a). We then investigated mitochondrial functions. Although
no difference in mitochondrial membrane potential (measured by
Mitotracker) was observed between control and Hsf1-ablated LSPCs
4
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Fig. 3 | HSF1 DNA binding is required for HSF1 function, and deletion of
HSF1 suppresses LSC proliferation and increases LSC apoptosis. a Scheme of the
structure of wild type and mutant alleles of HSF1. DBD, DNA binding domain; HR,
hydrophobic heptad repeat; RD, regulatory domain. HSF1 R71G is an inactive and
HSF1ΔRDT (deletion of regulatory domain and substitution of leucine at amino acid
395 in the suppression domain of the trimerization with glutamic acid, L395F) is an
active mutant. b Expression of HSF1 and its mutants (n = 3 independent replicates).
c Colony numbers formed using MLL-AF9 Hsf1ﬂ/ﬂcreER LSCs transduced with empty
vector, HSF1 WT, inactive R71G mutant, or active ΔRDT mutant in the presence
(deletion of endogenous Hsf1) or absence of 200 nM 4-OHT (n = 3 independent

replicates). *p = 0.000605, **p = 2.39 × 10−5. d EdU incorporation of MLL-AF9 Hsf1ﬂ/
f
creER LSPCs in the presence of absence of 200 nM 4-OHT (n = 3 independent
replicates). *p = 0.00016, **p = 5.45 × 10−6. e, f Percentages of Annexin V+
(e, *p = 0.0016) or Caspase-3+ (f, *p = 5.17 × 10−5) MLL-AF9 Hsf1ﬂ/ﬂcreER LSPCs treated
with or without 200 nM 4-OHT (n = 3 independent replicates). g Protein synthesis
measured by OP-Puro incorporation in MLL-AF9 Hsf1ﬂ/ﬂcreER LSPCs treated with or
without 200 nM 4-OHT (n = 3 independent replicates). *p = 0.00151. In (c–g), twotailed t test was used, data are presented as mean values ± SEM. Source data are
provided as a Source Data ﬁle.

(Fig. 5b), production of mitochondrial superoxide (MitoSOX) and
ROS (measured by H2-DCFDA and CellROX) was signiﬁcantly
increased in Hsf1-ablated LSPCs (Fig. 5c–e), which may contribute to
the increased apoptosis observed (Fig. 3e–f).
We next measured the oxygen consumption rates (OCRs) and
extracellular acidiﬁcation rates (ECARs) of LSCs directly using a Seahorse Bioscience XF96 extracellular ﬂux analyzer. In this assay, the
administration of oligomycin inhibits ATP synthase, resulting in a
reduction in mitochondrial respiration or OCR. The injection of Carbonyl cyanide-4 (triﬂuoromethoxy) phenylhydrazone (FCCP) will
enhance electron ﬂow through the electron transport chain (ETC) and
drive maximal oxygen consumption by complex IV. A mixture of
rotenone (a complex I inhibitor) and antimycin A (a complex III inhibitor) will shut down mitochondrial respiration and enable the determination of the contribution of nonmitochondrial respiration52. We
found that in the murine MLL-AF9 AML model, MLL-AF9 transduced
cKit+Lin− cells had higher OXPHOS activity than non-transduced BM
cKit+Lin− cells (Supplementary Fig. 3a). In addition, Hsf1 ablation signiﬁcantly decreased OCR and ECAR in LSPCs (Fig. 5f, g). Consistent
with reduced OCR, ATP production from both OXPHOS and glycolysis
was reduced by 4-OHT-induced Hsf1 ablation compared with the
control (Fig. 5h). The apparent lack of compensation of ATP production by increased glycolysis in Hsf1-ablated LSPCs suggests that LSPCs
are in crisis − decreased proliferation (Fig. 3d), increased ROS production (Fig. 5d, e), and increased apoptosis (Fig. 3e). The inability to
alter glycolysis to compensate for ETC and TCA cycle dysfunction
could also be due to Hsf1 ablation impairing the expression of genes
related to glycolysis (Supplementary Fig. 3b)53. To determine how Hsf1
depletion decreases OXPHOS, we measured changes in metabolite
proﬁles in Hsf1ﬂ/ﬂcreER LSPCs 36 h after 4-OHT treatment. Using highresolution mass spectrometry, we measured cellular metabolites in
LSPCs, particularly the TCA cycle intermediates, which supply substrate for OXPHOS directly through the electron transport chain and
found that Hsf1 ablation decreased fumarate and malate levels (Fig. 5i),

consistent with an impaired TCA cycle. We further tested this by tracing the cellular levels of 13C6-glucose-derived metabolites using gas
chromatography/mass spectrometry (GC/MS). Hsf1 ablation reduced
the levels of lactate, citrate, glutamate, succinate, malate, and aspartate (Fig. 5j, Supplementary Fig. 3c). These data demonstrate that Hsf1
ablation impairs ATP production through dysregulation of the TCA
cycle at multiple levels, resulting impaired OXPHOS activity.
To identify critical aspects of the TCA cycle directly disrupted by
Hsf1 ablation, we examined expression of key ETC complex I, II, III, IV
and V components by Western blotting. Hsf1 ablation did not alter the
protein levels of the key complex I, III, IV, and V subunits, but signiﬁcantly reduced the complex II components succinate dehydrogenase (SDH) A and SDHC (Fig. 5k). As HSF1 binds Sdhc directly
(Fig. 4h), downregulation of Sdhc was likely regulated at the transcription level by HSF1. qRT-PCR analysis conﬁrmed that the expression of both Sdha and Sdhc was compromised at the steady state
mRNA level in 4-OHT-treated LSCs (Fig. 5l). As succinate is the metabolic substrate and fumarate is the product for ETC complex II,
decreased fumarate and malate levels suggested a defect in ETC
complex II activity (Fig. 5i, j). Consistent with this prediction, ETC
complex II activity was markedly decreased in Hsf1-ablated LSPCs
compared with control LSPCs (Fig. 5m). These data suggest that SDH is
a key enzyme involved in the reduction of OXPHOS caused by HSF1
ablation and is consistent with the strong dependency on the ETC
complex II in AML12,54.
To investigate if downregulation of SDH plays a critical role in Hsf1
ablation-induced LSC dysfunction, we investigated if overexpression
of SDHC could restore defects induced by Hsf1 ablation. We found that
overexpression of SDHC enhanced cell growth and colony formation
of Hsf1ﬂ/ﬂcreER cells in the presence of 4-OHT in vitro, but overexpression of SDHC did not change the basal level of LSPC growth
(Fig. 5n–p). In addition, overexpression of SDHC signiﬁcantly restored
the impaired OXPHOS and the ETC complex II activities (Fig. 5q, r).
Importantly, overexpression of SDHC partially accelerated the delayed
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Fig. 4 | HSF1 regulated genes are involved in multifaceted LSC functions.
a–c RNA-seq analysis of sorted Contol (Con) or Hsf1KO MLL-AF9 LSCs (isolated
from 2 full blown individual leukemia mice for each genotype). Hsf1 ablation (a)
downregulated its known targets—heat shock protein genes; (b) upregulated genes
related to myeloid differentiation (Itgam, Elane, Mpo) and downregulated stemness
related genes (CD34, Flt3, Bcat1), and (c) genes related to OXPHOS. d–f GSEA
revealed that Hsf1 deletion impaired stem cell signature (d), down-regulated genes

related to OXPHOS (e) and TCA cycle (f). g CUT&RUN peak call enrichment analyses. KEGG and Gene ontology terms derived from genes involved in top 8000
peaks. h CUT&RUN demonstrated HSF1 binds Sdhc directly. H3K4me3 shows that
HSF1 binding occurs in active chromatin region. Binding to genes encoding heat
shock proteins (Hspd1 and Hspe1) and IgG binding were used as positive and
negative controls, respectively.

AML development induced by Hsf1 ablation in vivo (Fig. 5s), suggesting
that the HSF1-SDHC axis is an important contributor to LSC selfrenewal and AML maintenance.

sublethally irradiated (2.5 Gy) NSGS (triple transgenic NSG-SGM3 mice
expressing human IL3, GM-CSF and SCF) mice. We found that, like Hsf1
ablation in mice, genetic knockdown of HSF1 in HSPCs did not affect
the BM repopulating capacity of human CD34+ HSPCs (Fig. 6b).
Although HSF1 is expressed ubiquitously, HSF1 transcript
expression is signiﬁcantly lower in normal human CD34+ HSPCs than in
CD34+ leukemic blasts (Fig. 6c). Immunoblotting and immunohistochemistry showed that HSF1 protein is also highly expressed in
leukemic blasts, while its expression is very low to negligible in normal
BM cells (Fig. 6d, e, Supplementary Fig. 4a). In addition, there is no
difference in HSF1 protein expression between non-stem cell

HSF1 is not required for human HSPC repopulation, but is critical for LSC self-renewal
To ascertain if HSF1 can be safely targeted in human AML, we ﬁrst
tested if deletion of HSF1 impacts human HSPC maintenance. Using the
CRISPR-Cas9-mediated genome editing system, we efﬁciently knocked
down human HSF1 in human BM CD34+ HSPCs (Fig. 6a). We then
transplanted HSF1 knockout or control human CD34+ HSPCs into
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populations and stem cell populations in AML given the diffuse nuclear
HSF1 positivity in all AML samples by HSF1 immunostaining (Fig. 6e,
Supplementary Fig. 6b). These results not only further substantiate
why HSF1 deletion does not have a signiﬁcant impact on human HSPC
function, but also clearly demonstrate that HSF1 protein is highly
expressed in human leukemia cells, with an overall high level in the
nucleus by immunohistochemical staining. Consistent with our patient
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analysis, analysis of different AML datasets from Oncomine (Supplementary Fig. 4b), TCGA (Supplementary Fig. 4c) and recently published data55 (Supplementary Fig. 4d, e) show that there is an overall
trend that HSF1 levels are higher in AML patients than healthy controls
and especially higher in AML with poor/complex cytogenetics or
adverse outcomes. Furthermore, analysis of TCGA data shows that
higher HSF1 expression correlates with a poor prognosis (Fig. 6f).
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Fig. 5 | HSF1 is a key regulator of oxidative phosphorylation in AML. For
experiments (a–m), Hsf1ﬂ/ﬂcreER mouse MLL-AF9 LSPCs were treated with or
without (Con) 200 nM 4-OHT for different times. a 2-NBDG uptake (n = 3 independent replicates). b Mitochondrial membrane potential (Mitotracker, n = 3
independent replicates). c Mitochondrial superoxide (Mitosox, n = 4 independent
replicates), *p = 0.0017. d, e Mitochondrial ROS levels measured by H2-DCFDA
(d, n = 4 independent replicates, *p = 0.0106) or CellROX (e, n = 3 independent
replicates, *p = 0.0016). f, g OCR (f, *p = 5.9 × 10−18, **p = 4.3 × 10−11) and ECAR
(g, *p = 5.3 × 10−7, **p = 8.8 × 10−8) measured by Seahorse (n = 8, independent
replicates each). h ATP production (n = 3 independent replicates). *p = 3.57 × 10−5,
**p = 0.000795. i Leukemia cell intermediate metabolites (n = 5 independent
replicates) using high-resolution Gas chromatograph mass spectrometry (GC/MS).
j 13C6-Glucose tracing (measuring leukemia cell intermediate metabolites) using
GC/MS. Left, illustration of glucose metabolism. White circles, 12C carbons; blue
circles, 13C carbons. M + 2 and M + 3 refer to the number of 13C carbons.; Right, TCA
intermediates: citrate (*p = 0.00167), succinate (*p = 0.0121), fumarate, and malate
(*p = 0.0011) and intracellular metabolites: pyruvate, alanine, lactate (*p = 0.0146),
glutamate (*p = 0.00014), and aspartate (*p = 0.00098). Data are the isotopologue
distribution relative to abundance and normalized to the control group, plotted as

mean values and individual data points from n = 5 cultures. k Expression of key
electron transport chain complex (ETC) I, II, III, and IV components by Western
blotting (n = 3 independent replicates). l qPCR analysis of expression of Sdha
(*p = 0.0008) and Sdhc (*p = 8.2 × 10−7) (n = 3 independent replicates). m ETC
complex II activity (*p = 0.00575) (n = 3 independent replicates). n Expression of
exogenous SDHC protein in Hsf1ﬂ/ﬂcreER LSPCs (n = 2 independent replicates).
o, p Leukemia cell proliferation (o, *p = 0.00078) and colony formation
(p, *p = 0.00024) in empty vector or SDHC transduced Hsf1ﬂ/ﬂcreER LSCs in the
presence or absence of 200 nM of 4-OHT (n = 3 independent replicates, each).
q OCR in empty vector or SDHC transduced Hsf1ﬂ/ﬂcreER LSPCs treated with or
without 200 nM 4-OHT (n = 7 independent replicates). *p = 0.00066, **p = 2.2 ×
10−10, ***p = 4.86 × 10−6. r ETC complex II activity in empty vector or SDHC transduced Hsf1ﬂ/ﬂcreER leukemia cells treated with or without (Con) 200 nM 4-OHT
(n = 4 independent replicates). *p = 0.00056, **p = 0.0044. In (c–e, h, j, l–m, r), twotailed t test was used, data are presented as mean values ± SEM. s Survival curve of
sublethally irradiated recipient mice receiving vector or SDHC transduced Hsf1ﬂ/
ﬂ
creER LSCs treated with vehicle (n = 5 mice/group) or TAM (n = 9 mice/group).
*p = 0.0001. Source data are provided as a Source Data ﬁle.

Fig. 6 | HSF1 is not required for normal human HSPC repopulation but highly
expressed in AML cells. a Relative expression of HSF1 mRNA in Cas9 (Con)- or
CRISPR-Cas9-mediated HSF1 knockdown (HSF1KD) in human BM CD34+ HSPCs
(n = 3 independent replicates). *p = 0.01017. b Engraftment of Control- or CRISPRCas9-mediated HSF1 knockdown in human BM CD34+ cells (n = 4 mice/group).
c Relative HSF1 mRNA in sorted human healthy BM CD34+ cells and AML CD34+
blasts (n = 4 independent replicates). *p = 0.0041. In (a, c), two-tailed t test was

used, data are presented as mean values ± SEM. d Expression of HSF1 protein in
normal (negative lymphoma staging BM, n = 3 independent replicates) and primary
AML BMs (n = 5 independent replicates). Actin is used as a load control.
e HSF1 staining of HSF1 (nuclear, red) and CD34 (membranous, brown) doublestaining of normal and AML BM cells; Scale bar, 20 μM; n = 16 primary AML samples.
f The expression of HSF1 correlated with AML patient prognosis (TCGA AML data).
Source data are provided as a Source Data ﬁle.

We then tested the functional impact of HSF1 ablation on the selfrenewal and maintenance of human LSCs. Consistent with higher HSF1
expression in leukemic blasts, knockdown of HSF1 (70–90% of
knockdown efﬁcacy, Supplementary Fig. 5a) signiﬁcantly reduced
human leukemia blast growth in vitro (Supplementary Fig. 5b) and
repopulation in NSGS recipient mice (Fig. 7a, see Supplementary
Information for limited information on AML samples used for transplantation), ATP production (Fig. 7b) and extended the survival of
recipient mice (Supplementary Fig. 5c). Given the dependency of
human LSCs on HSF1, we tested if a small molecule HSF1 inhibitor
could speciﬁcally kill leukemia cells, while sparing normal HSPCs.
Previously reported HSF1 pathway inhibitors have been evaluated in
cellular and mouse xenograft cancer models56–58. However, most either
act in an indirect manner in the HSF1 pathway or have an unknown

mechanism of action. SISU-102 (recently published as DTHIB, Direct
Targeted HSF1 InhiBitor) has been shown to be a direct and selective
small-molecule HSF1 inhibitor which physically engages HSF1 and
selectively stimulates degradation of the active, homotrimeric, nuclear
form of HSF1. SISU-102 robustly inhibits the HSF1 cancer gene signature and drives prostate cancer tumor regression in multiple mouse
models59. Importantly, SISU-102 administration elicited no observable
adverse effects on mouse behavior, weight, or organ histopathology59.
We ﬁrst tested the impact of SISU-102 on murine MLL-AF9 leukemia
cells and human AML cell lines. As shown in Fig. 7c, SISU-102 clearly
inhibited the expression of the HSF1 targets, HSP90 and SDHC, and
HSF1 itself, in a dose-dependent manner and strongly suppressed the
growth and OCRs of murine MLL-AF9 Hsf1ﬂ/ﬂcreER leukemia cells and
human MV4–11 and NOMO-1 AML cells (Fig. 7d, e). Importantly,
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Fig. 7 | HSF1 is critical for maintenance of LSC self-renewal. a Engraftment of
three different primary AML LSCs in the presence or absence of CRISPR-mediated
HSF1KD (started 4 mice/AML). *p = 0.0404, **p = 0.0003, ***p = 0.0006. b ATP
production in control or HSF1 knockdown AML cells (post-transplantation from a)
measured by Seahorse assay (n = 3 independent replicates). AML-a: *p = 0.0046.
**p = 0.0349; AML-b: *p = 0.0201. **p = 0.0124; AML-c: *p = 0.0325. **p = 0.0033;
c The expression of HSP90, SDHC, and HSF1 proteins in SISU-102 treated mouse
MLL-AF9 cells and the human AML cell lines MV4–11 and NOLM-1 (n = 3 independent replicates). ACTIN is used as a load control. d Cell growth of murine MLL-AF9
cells (*p = 1.6 × 10−5, **p = 3.1 × 10−5, ***p = 6.1 × 10−5) and human AML cell line MV4–11
(*p = 4.8 × 10−3, **p = 2.3 × 10−4, ***p = 1.6 × 10−4) and NOLM-1 (*p = 6.3 × 10−4, **p = 3.01
× 10−5, ***p = 6.38 × 10−5) in the presence of absence of SISU-102 (n = 3 independent

replicates). e OCR in Hsf1ﬂ/ﬂcreER LSCs (*p = 8.87 × 10−31, **p = 1.09 × 10−7) or human
AML cell line MV4–11 (*p = 4.89 × 10−13, **p = 4.97 × 10−12) and NOLM-1 (*p = 1.19 ×
10−18, **p = 0.00028) treated with or without SISU-102 (n = 8 independent replicates). f Engraftment of human AML cell line MV4–11 (n = 5 mice/group, *p = 9.8 ×
10−5) or three different primary AML cells in the presence or absence of SISU-102.
AML-d: *p = 1.8 × 10−5, n = 4 mice/group, and AML-e: *p = 8.98 × 10−6, Con n = 4 mice,
SISU-102, n = 5 mice; AML-f: *p = 0.0011, Con n = 5 mice, SISU-102, n = 4 mice.
g Engraftment of human BM CD34+ HSPCs treated with (n = 4 mice) or without
(n = 3 mice) SISU-102 (5 mg/kg, IP, daily). In (a, b, d–f), two-tailed t test was used,
data are presented as mean values ± SEM. Source data are provided as a Source
Data ﬁle.

administration of SISU-102 (5 mg/kg; control group injected with
proportional amount of DMSO) alone strongly suppressed the
engraftment of MV4–11 and three independent primary human AML
cells in NSGS recipient mice and extended the survival of recipient
mice (Fig. 7f, Supplementary Fig. 5d). Furthermore, the combination of
SISU-102 with Ara-C further suppressed the engraftment of human
AML cells (Supplementary Fig. 5e). Similar to Hsf1 genetic knockdown
results (Fig. 6b), SISU-102 administration had no overt impact on
human BM CD34+ HSPC engraftment (Fig. 7g). Taken together, these
data suggest that pharmacologically targeting HSF1 speciﬁcally
impairs human LSC self-renewal, while sparing normal HSPC selfrenewal.

expression of HSF1 in normal human BMs compared to diffuse positivity of nuclear HSF1 in AML BMs, regardless of CD34 positivity
(Fig. 6e), suggests that HSF1 may be more useful than CD34 for monitoring malignant status in AML. To investigate if the expression of
HSF1 correlates with AML status, we retrospectively collected 477
cases from 162 patients, 39 of which had serial BM biopsies at diagnosis, remission, and relapse. The H-Score based on HSF1 immunohistochemical staining, calculated by Extent (%) x nuclear intensity (0,
1+, 2+, 3+) of staining showed consistent and statistically signiﬁcant
changes in nuclear HSF1 expression in these serial specimens: high at
diagnosis, low at remission, and elevated again at relapse (Fig. 8a,
Supplementary Fig. 6a). For example, when the nuclear HSF1 level is
low at relapse (Fig. 8b) and further reduced during follow-up (Fig. 8c);
this suggests remission; indeed, patients with this HSF1 staining pattern did not experience disease relapse during the follow-up interval.
In contrast, during remission, even though the biopsies showed no
increase in blasts (by immunohistochemistry, ﬂow cytometry and
manual counting), the residual small clusters of HSF1-positive cells
(Fig. 8d), although we do not know whether they are residual LSCs with

Expression of HSF1 serves as a marker to monitor malignant
status in AML
In the examination of clinical cases, we frequently observe a hypocellular marrow (5–10% of cellularity) from AML patients at Day14 postchemotherapy, with no or rare blasts detected by CD34 immunostaining, manual counting and/or ﬂow cytometric analysis. The very low
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Fig. 8 | Expression of HSF1 might serve as a marker to monitor AML status.
a HSF1 H-score index in AML samples at diagnosis, remission, or relapse (n = 39
primary AML samples). Box plots show median and ﬁrst/third quartiles. ANOVA
with LSD post-hoc analysis was used, *p = 0.0001. b–f Representative pictures
showing 2 different HSF1 staining patterns in AML patients. b–c Pattern 1,

HSF1 staining at remission (b) and follow up (c). d–f Pattern 2, HSF1 staining at
remission (d), follow up (e) and relapse (f). Note that (b) and (d) are 2 weeks post
chemotherapy, BM shows 5–10% of cellularity. The insets in (b) and (d), are
HSF1 staining at AML diagnosis. Scale bar, 20 μM. Source data are provided as a
Source Data ﬁle.

altered immunophenotype or metabolic status due to treatment8,
which persist and are increased in the follow-up (Fig. 8e, f), indicate a
risk of relapse, and indeed patient with this HSF1 staining pattern
relapsed later. These data suggest that HSF1 nuclear expression might
be a biomarker to monitor AML status.

experiments (Supplementary Table), only one is MLL-rearranged. The
generalized HSF1 nuclear positivity in all tested AML samples,
regardless of associated cytogenetic/molecular mutations, further
support a broader role of HSF1 in AML. Recent studies have shown that
AML is primarily dependent on mitochondrial OXPHOS to generate
ATP for survival11,48,49. Consistent with this, AML blasts have higher
mitochondria levels than non-malignant HSCs49,66. An increase in
mitochondrial mass, mitochondrial membrane potential and OXPHOS
predicts AML chemoresistance, while inhibition of OXPHOS can
restore sensitivity to chemotherapy9. In addition to the classical HSF1
targets, speciﬁcally heat shock proteins that function as protein chaperones, the CUT&RUN experiments showed that HSF1 also activates
genes involved in AML metabolism. We further determined that Sdhc is
a direct HSF1 target and Hsf1 ablation suppressed the expression of
SDHC and its family member SDHA, which impaired AML OXPHOS
activity. Importantly, overexpression of SDHC partially rescued the
LSC functional defects that occur as a consequence of Hsf1 ablation,
although no overt impact on basal LSC growth and engraftment was
observed. These results are consistent with the crucial role of HSF1 in
regulating mitochondrial metabolism and biogenesis to prevent oxidative damage and increase OXPHOS, which has been reported in
other systems17,67–69, and further supports the notion that ETC complex
II activity is essential for LSC survival70.
Based on the dependence of AML on mitochondrial oxidative
phosphorylation, targeting OXPHOS in AML has been proposed as a
promising therapeutic approach15. Furthermore, the reduced OXPHOS
activity in HSF1-ablated LSCs, as well as the multitude of other functions driven by HSF1 that support cancer cell proliferation and
survival18,58,71,72, points to HSF1 inhibition as a potential therapeutic
alternative in AML. While targeting HSPs in AML has been explored
with promising results73,74, HSP inhibition interrupts a feedback loop
that ultimately increases HSF1 activity and thus compromises treatment efﬁcacy75,76. We suggest that targeting HSF1 directly will be more
attractive as this strategy can simultaneously downregulate the
expression of protein chaperones, impair LSC OXPHOS activity and
inhibit a range of oncogenic signaling, survival and metastasis programs that are HSF1-dependent. Moreover, given the high plasticity of
AML cells that enables them to adapt their metabolism and ensure
their survival during chemotherapy38, targeting HSF1, either alone or in

Discussion
AML remains largely incurable, and it is important to identify new
therapeutic targets for AML given the currently limited treatment
regimens2. Our study demonstrates that HSF1 is speciﬁcally required
for LSC self-renewal, while being dispensable for normal hematopoiesis. In part, HSF1 maintains LSC self-renewal through the regulation of
genes involved in maintaining LSC stemness and ETC complex IImediated OXPHOS.
Given the critical roles of HSF1 in the maintenance of normal
cellular homeostasis17,19,60, it is somewhat surprising that Hsf1 ablation
has no signiﬁcant impact on both steady-state and stressed multilineage hematopoiesis. However, this is not completely unpredicted
since global Hsf1−/− mice have normal development in the absence of
acute stress61,62. This may be attributable to partial functional redundancy between HSF1 and other HSF family members, such as HSF2, in
the regulation of cellular protein homeostasis63–65. Indeed, HSF1 and
HSF2 can bind to the same cis-acting promoter sequences, and HSF2
activates multiple genes in common with HSF1 in response to febrile
stress64. In addition, our results are consistent with two recent reports
demonstrating that HSF1 is dispensable for normal HSC function,
although HSF1 does function in HSC ﬁtness and protein homeostasis in
aged mice30,39. Importantly, the very low levels of HSF1 protein
observed in non-malignant human BM biopsy specimens compared to
human AML samples, mouse xenograft experiments using HSF1
knockdown human BM CD34+ HSPCs, and inhibition of HSF1 function
with SISU-102 further support the idea that HSF1 is not required for
human HSPC self-renewal. Thus, there is potential for targeting
HSF1 in AML.
In contrast, our data clearly demonstrate that HSF1 is required for
the maintenance of LSC functions in both MLL-AF9-induced murine
and human primary AMLs. It should be noted that the role of HSF1 in
LSC maintenance is not limited to AML with MLL rearrangement, as
among the six primary AML samples used for xenotransplantation
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combination with conventional agents such as Ara-C could present
additional options to target these transient leukemic-regenerating
cells8. Previous reports suggest targeting HSF1 in AML through
microRNAs77 or via inhibition of translation initiation factor eIF4a34.
However, directly targeting HSF1 with small molecules such as SISU102 may have advantages with respect to absorption and pharmacokinetic features and would limit potential toxicity from “off target”
pathway modulation.
In addition to providing a rationale for targeting HSF1 for AML
treatment, our data also suggest that measurement of nuclear HSF1
levels should be further explored as a peripheral biomarker to monitor
AML status. Currently, CD34 is the only routinely used clinical marker to
enumerate leukemia blasts. However, the blasts in AML with monocytic
differentiation (e.g., acute monocytic/monoblastic leukemia, AML with
mutated NPM1), acute erythroid leukemia, and acute megakaryocytic
leukemia are typically negative for CD34. Monitoring of these leukemias largely relies on morphologic examination, and molecular mutation studies. We provide strong evidence that all tested AML samples,
regardless of whether they have recurrent cytogenetic abnormalities or
not, expressed higher levels of nuclear HSF1 proteins than normal BM
cells, and the expression of HSF1 is not limited to CD34+ blasts. A prospective clinical study using HSF1 immunohistochemical staining,
including HSF1 phosphorylation status78, is warranted. Correlating
these characteristics with ﬂow-cytometry and molecular studies could
validate the use of HSF1 as a biomarker to predict AML status.
In addition, the combination of monitoring HSF1 expression by
immunostaining along with HSF1 small molecular inhibitors may be a
useful strategy to target AML residual disease just as done for PD-L1
expression with Keytruda and HER2 expression with Trastuzumab in
the recently described companion diagnostics79.
Among the mechanisms that result in increased levels of nuclear
HSF1, in a broad range of cancers, include ampliﬁcation of the HSF1
gene located within chromosome 8q24.3, reduced expression of the
HSF1 degradation F box E3 ligase Fbxw7, activation by loss of p53 and
increased HSF1 transcription by oncogenic signaling pathways such as
NOTCH signaling30,80–82. Other potential contributing factors are the
accumulation of the mutant cancer proteome and rapid proliferation
of cancer cells, which may select for increased levels and activity of
HSF1 via additional mechanisms. AML is heterogeneous and characterized by a multitude of chromosomal abnormalities and somatic
mutations, presenting a requirement for increased levels of the protein
quality control machinery to cope with the mutant cancer proteome.
Among the many functions of HSF1 in cancer, this increase could, in
part, underlie the high dependence on HSF1 for LSC self-renewal. The
published AML transcriptome datasets and the large number of AML
immunohistochemical staining results demonstrate signiﬁcantly
higher HSF1 expression in different types of AML in general. It should
be noted that TP53 is frequently mutated in AML with complex
karyotype83,84, which may account for relatively higher HSF1 mRNA
expression in AML with complex karyotype (Supplementary Fig. 4b, c)
given that wild type TP53 suppresses HSF1 expression and the mutant
cancer genome85. Thus, targeting a common non-oncogenic and nonessential molecule that is relevant to the progression of different types
of AML irrespective of the underlying molecular and cytogenetic
aberrations may hold clinical promise. Collectively, these data indicate
that HSF1 controls multiple signaling pathways that are required for
LSC maintenance, especially OXPHOS metabolism, which is critical for
LSC functions, and suggest that targeting HSF1 may have broad antileukemic effects.

Methods
Mice
The mouse experiments were conducted under approved protocol
2020-0031 of the Institutional Animal Care and Use Committee
(IACUC) of Case Western Reserve University. The mice were kept in
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individually ventilated cages under Speciﬁc Pathogen Free conditions
at Case Western Reserve University. The mice were fed ad libitum at
24 °C, 50% humidity and a 12:12 h light/dark cycle. The Hsf1ﬂ/ﬂ conditional mouse model has been described previously37. The ROSACreERT2 mice were kindly provided by Dr. Yiying Zhang86 and used
previously87. Vav-Cre mice (Stock 008610) and the transplant recipient
CD45.1 mice (stock 002014) and NSGS mice (stock# 013062) were
purchased from Jackson Laboratory. All the mouse strains are in a
C57BL6 background and were used at 8–12 weeks old and included
male and female mice.

Human samples and cell lines
De-identiﬁed human AML cells were obtained through the CRWU
Hematopoietic Biorepository & Cellular Therapy Core (IRB
STUDY20210216) and the ﬂow cytometry laboratory at the University
of Iowa (Institutional IRB Approval #201508729). The mononuclear
cells were puriﬁed by Ficoll-density gradient centrifugation and enriched for CD34+ or lineage− leukemic stem/progenitor cells by positive
or negative selection using the EasySep™ Human CD34 Positive
Selection Kit (#17856) or the Human Progenitor Cell Enrichment Kit
(#19356), respectively (StemCell Technologies), depending on CD34
positivity of the blasts. Frozen human BM CD34+ cells (#70002.4) were
purchased from StemCell Technologies.
The Human AML cell lines, NOMO-1 (ACC 542) purchased from
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell
Cultures and MV4–11 (CRL-9591), were purchased from ATCC and
cultured in RPMI-1640 media (Gibco) supplemented with 10% FBS (GE
Healthcare) and 1% Pen/Strep (Gibco).

HSPC and LSPC isolation, proliferation, apoptosis and mitochondrial ROS analysis
We used the following antibodies from e-Bioscience and BD Biosciences: B220, CD3, CD4, CD8, CD11b, CD11c, CD16/32, CD34, CD45.1,
CD45.2, CD117, Gr-1, Sca1, and Ter119. The antibody was used at a 1:100
for ﬂow cytometry. For isolation of lineage−c-kit+Sca-1+ (KLS) cells,
whole BM cells were incubated with a cocktail of lineage antibodies
from BD Biosciences (biotinylated anti-mouse antibodies directed
against CD3e, CD11b, B220, Gr-1, Ter119) followed by lineage depletion
using BD IMag streptavidin particles Plus-DM, then stained with Sca-1
Percp-Cy5.5, CD117-BV421, and streptavidin PE-CF594. For HSPC analyses, lineage depletion was omitted, and the following antibodies were
used when appropriate: PE-conjugated lineage markers (CD3, CD4,
CD5, CD8, B220, Gr-1, C11b, and Ter119) or biotinylated lineage markers
plus streptavidin PE-CF594, Sca-1 PE-Cy5.5, CD117-BV421, CD34-A700
or FITC, CD16/32-PE, CD135-APC, CD127-FITC, or CD150-PECy7, CD48APC or CD48-PE. For leukemia cell EdU incorporation, proliferation
(Ki67+), and caspase3/apoptosis analyses, the following antibodies
were used when appropriate: Gr-1-FITC, CD11b-PE or FITC and Sca1-PE
or PE-Cy5, CD34-A700, CD117-BV421 or PECy7, CD16/32-APC or -PECy7,
CD45.1-APC or A700, CD45.2-PECy7, Ki67-PE, and caspase3-PE.
For in vitro EdU (5-ethynyl-2′-deoxyuridine) labeling, EdU was
added to culture media to a ﬁnal concentration of 10 μM. 1 h later, cells
were collected and stained ﬁrst with surface marker (see above), followed by EdU staining using a EdU-APC staining kit (BD Biosciences).
For caspase-3 staining, cells were ﬁrst stained with surface markers to
deﬁne the progenitor population, followed by ﬁxation and permeabilization with Cytoﬁx/Cytoperm (BD Biosciences) and intracellular
staining with Caspase3-PE. For Annexin V staining, cells were ﬁrst
stained with surface markers to deﬁne the progenitor population,
washed in 1X binding buffer, and then stained with AnnexinV-APC
antibody for 20 min. Cells were resuspended in binding buffer and 5 μl
of 7-AAD Staining Solution was added 5 min before analysis using ﬂow
cytometry.
For measuring glucose incorporation and mitochondrial ROS, 5 ×
105 leukemia cells were ﬁrst stained with Mac1-PE or-APC, c-kit-BV421
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or -A700 to deﬁne the progenitor population, then labeled with
the following agents (all from ThermoFisher Scientiﬁc) for 30 min
at 37 °C: 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)−2Deoxyglucose, 10 μM, N13195), CellRox (0.75 μM, C10422) or H2DCFDA (2 μM, D399).
For measuring mitochondrial superoxide and mitochondrial
membrane potential, 5 × 105 leukemia cells were labeled with MitoSox
(2.5 μM, 15 min, M36008) or Mitrotracker green (5 nM, 30 min, M7514)
at 37 °C ﬁrst, then stained with Mac1-PE or-APC, c-kit-BV421 or -A700 to
deﬁne the progenitor population.
For cell separation based on endogenous ROS levels, leukemia
cells were stained with 8 μM CellRox for 15 min at 37 °C, washed with
PBS with 2% FBS, and were collected by cell sorting as described
previously10.
LSRII was used for all the analyses, and FACSAria was used for cell
sorting. Data were analyzed using FlowJo (TreeStar).
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(ab14713, 1:800 dilution), SDHA (ab14715, 1:5000 dilution), SDHB
(ab14714,1:800 dilution), SDHC (ab155999,1:800 dilution), SDHD
(ab189945,1:800 dilution), UQCRC2 (ab14745,1:800 dilution), MTCO1
(ab14705,1:800 dilution), ATP5B (ab14730,1:800 dilution) (all from
Abcam), DDK/FLAG (Origene, TA180144, 1:1000 dilution) or beta-actin
(Santa Cruz, sc-47778, 1:2000 dilution). Membranes were scanned with
the ChemiDoc Touch Imaging system (Bio-Rad).

In vitro colony-forming assays
Fluorescence-activated cell sorting (FACS). FACS-sorted (lin–c-Kit
+
Sca1–CD16+CD34+) MLL-AF9 leukemia cells were plated (100–200
cells/96-well plate, 500–2000/24- or 6- well plate) in methylcellulose
media (Methocult M3434, StemCell Technologies) in the presence or
absence of 4-hydroxytamoxifen (4-OHT, 200 nM, Sigma T-176). For
human leukemia cell colony-forming assays, Methocult H4034 was
used. Colonies were counted after 5–7 days and replated with the same
numbers of cells.

Electron transport chain complex II activity assay
MLL-AF9 Hsf1ﬂ/ﬂCreER leukemia cells (5 × 105/well) were treated with
4-OHT (200 nM) for 36 h, samples were prepared, and the enzyme
activity was quantiﬁed by the colorimetric Complex II Enzyme Activity
Microplate Assay Kit according to the manufacturer’s protocol
(Abcam, ab109908).

Protein synthesis
For Click-iT Protein Synthesis assay, cells were ﬁrst stained with surface
markers to deﬁne the progenitor population, then followed by staining
using a Click-iT Plus OPP Alexa Fluor 647 Protein Synthesis Assay Kit
(ThermoFisher Scientiﬁc).

Plasmid constructs and virus production
The plasmid, pMSCV-MLL-AF9, was described previously87. Sdhc cDNA
were purchased from Origene (#RC205010), and HSF1 (human) Wild
type, an active (ΔRD, deletion of RD along with substitution of a
hydrophobic amino acid in the HR-C L395F), and an inactive (R71G,
cannot bind to the heat shock element) mutant HSF1 were kindly
provided by Dr. Nakai46 and were used as templates for subcloning into
BamH1/EcoRI sites of pMSCV-IRES-mCherry using in-fusion following
the manufacturer’s instructions (Clontech). 293T cells were transiently
transfected with MSCV vectors with pCL-Eco or pLV vectors with
psPAX2 and pMD2.G using lipofectamine 3000 for retrovirus and
lentivirus production, respectively.

RNA extraction and quantitative real-time PCR analysis
RNA was extracted using a NucleoSpin RNA Kit (Takara). Equal
amounts of RNA were used for reverse transcriptase reactions,
according to the manufacturer’s instructions (SuperScript III FirstStrand Synthesis SuperMix, Invitrogen). Quantitative PCR (qPCR) was
performed with the iTaq Universal SYBR Green Supermix (Bio-Rad).
Gene expression levels were normalized to beta-actin. The primer
sequences used are: Sdha forward 5′-AAGCTCTTTCCTACCCGATCAC3′, Sdha reverse 5′-AATGCCATCTCC AG TT GTCCT-3′; Sdhc forward
5′-TCTTCCCGCTCATGTACCAC-3′, Sdhc reverse 5′-GACAACA CAGCA
AGAACCACGA-3′; B2m/β2-Microglobulin forward 5′- CTG TATGCTATC
CAGAAAAC CC-3′, B2m/β2-Microglobulin reverse 5′-TCACATGTCTC
GAT CCCAGTAG-3′.

Western blotting
Cells were lysed in 1x lysis buffer (10X RIPA Buffer, Cell Signaling
Technologies, #9806S) with protease inhibitors. Subsequently, 50 μg
of total cellular lysates were loaded in 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels, electrotransferred onto Nitrocellulose (NC) membrane and immunoblotted
with antibodies to HSF1 (ENZO ADI-SPA-901-F, 1:1000 dilution), HSP90
(Cell Signaling Technologies, 4874S, 1:1000 dilution), NDUFA9
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CRISPR/Cas9-mediated disruption of HSF1
CRISPR/Cas9-mediated deletion of HSF1 was conducted using published protocol88. Protospacer sequences for HSF1 were identiﬁed
using the CRISPRscan algorithm (www.crisprscan.org)89. DNA templates for sgRNAs were made using the protocol described by Li et al90
using HSF1 sgRNA primer: taatacgactcactataGGGGACCCTCG TGAGCGACCgttttagagctagaa. For human primary AML cells or CD34+ BM
HSPCs, 2 × 105 cells were used per electroporation using the Neon
Transfection System 10 μL Kit (Thermo Fisher Scientiﬁc, MPK1096). To
electroporate Cas9-sgRNA RNPs, 1.5 μg of sgRNA was incubated with
1 μg Cas9 protein (Invitrogen, A36496) for 20 min at room temperature, and electroporated using the following conditions: 1600V, 10 ms,
3 pulses. The electroporated cells were transferred immediately to a
24-well plate containing 0.5 ml of the corresponding growth medium
and then incubated for 48 h in a 5% CO2 incubator.

Seahorse assays
Cells were treated with 4-OHT (200 nM) or SISU-102 (5 μM) for 36 h,
then plated in XF96 cell culture microplate (Agilent Technologies,
102417-100). Experiments measuring oxygen consumption (OCR),
extracellular acidiﬁcation rate (ECAR) and total ATP production were
performed using a Seahorse XF Cell Mito Stress Test kit, as described
previously91. Brieﬂy, 1 × 105 cells per well (5 replicates) were seeded in
Poly-D-Lysine (Sigma, P6407)-coated 96-well XF96 microplates. Fortyﬁve min prior to analysis, the medium was replaced with Seahorse XF
media (Agilent Technologies, 102353-100) and the plate was incubated
at 37 °C. For OCR and ECAR, analyses were performed both at basal
conditions and after injection of 1 μM oligomycin (Sigma-Aldrich, Cat#
871744), 20 μM FCCP (Sigma-Aldrich, Cat# C2920), 1 μM Antimycin A
(Sigma-Aldrich, Cat# A8774), and 10 μM rotenone (Sigma-Aldrich,
Cat# R8875). For quantiﬁcation of ATP production rate from both
glycolytic and mitochondrial pathways and ATP rate index, analyses
were performed with injection of 15 μM oligomycin (Sigma-Aldrich,
Cat# 871744), 5 μM antimycin A (Sigma-Aldrich, Cat# A8774), and 5 μM
rotenone (Sigma-Aldrich, Cat# R8875).

Metabolic proﬁling for GC-MS
MLL-AF9 Hsf1ﬂ/ﬂcreER leukemia cells (1 × 106/samples, 5 replicates) were
treated with or without 4-OHT (200 nM) for 36 h and then washed 3
times with ice-cold PBS, 1 time with ice-cold distilled water, and then
immediately frozen in liquid nitrogen. Metabolites were extracted
using 1 mL of ice-cold methanol/acetonitrile/water (2:2:1) per sample.
Samples were then frozen in liquid nitrogen, followed by 10 min sonication. Samples were incubated at –20 °C for 1 h, followed by 10 min
centrifugation at 21,000 × g. Supernatants were transferred to autosampler vials and dried using a speed-vac. The resulting dried metabolite extracts were derivatized using methoxyamine hydrochloride
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Article
(MOX) and N,Obis (trimethylsilyl)triﬂuoroacetamide (TMS) and
examined by gas chromatography-mass spectrometry (GC-MS), as
previously described92,93. Brieﬂy, dried extracts were reconstituted in
30 μl of 11.4 mg/mL MOX in anhydrous pyridine, vortexed for 5 min,
and heated for 1 h at 60 °C. Next, 20 μl of TMS were added to each
sample. Samples were vortexed for 1 min and heated for 30 min at
60 °C. Samples were immediately analyzed using GC-MS.
13

C-glucose tracing for GC-MS

MLL-AF9 Hsf1ﬂ/ﬂcreER leukemia cells (10 × 106/samples, 5 replicates)
were treated with or without 4-OHT (200 nM) for 36 h. Culture
medium was replaced with glucose-free RPMI-1640 with 2000 mg/L
13
C-glucose for 60 min when it will be long enough for glucose to
label glycolysis and the TCA cycle above the limit of quantitation but
not so long that label mixing confounds interpretation. Following
incubation, cells were washed 3 times with ice-cold PBS, 1 time with
ice-cold distilled water, and then immediately frozen in liquid nitrogen. Tracing samples were processed using the above method for
proﬁling samples.

GC-MS instrumentation
GC separation was conducted on a Thermo Trace 1300 GC ﬁtted with a
TraceGold TG-5SilMS column. 1 μl of derivatized sample was injected
into the GC operating under the following conditions: split ratio = 20-1,
split ﬂow = 24 μl/min, purge ﬂow = 5 ml/min, carrier mode = Constant
Flow, and carrier ﬂow rate = 1.2 ml/min. The GC oven temperature
gradient was as follows: 80 °C for 3 min, increasing at a rate of 20 °C/
min to 280 °C, and holding at a temperature at 280 °C for 8 min. For
metabolic proﬁling, metabolites were detected using a Thermo ISQ
7000 mass spectrometer operated from 3.90 to 21.00 min in EI mode
(−70eV) using select ion monitoring (SIM). For tracing, metabolites
were detected in CI mode using SIM.
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for digital analysis. Digital slides were annotated using the Case Viewer
digital image analysis software 2.4. Five high power ﬁelds were selected
for each slide from regions with the highest concentrations of
immune-positive nuclei. A high-power ﬁeld area was deﬁned as 0.159
mm2. Digital quantiﬁcation scoring parameters were set to exclude
high background intensity and nonspeciﬁc staining. Digital scoring
parameters included number and proportion (extent %) of nuclei with
negative, weak positive, medium positive, and strong positive staining.
The H-score, calculated as Extent (%) x nuclear intensity (0, 1+, 2+, 3+)
of HSF1 staining, was reported.

RNA-Seq and transcriptome analysis
Total RNA was extracted from sorted LSCs (lin−c-kit+Sca1−CD16+CD34+)
from two full blown leukemia mice developed from MLL-AF9transduced Hsf1ﬂ/ﬂVav-Cre HSPCs and two full blown leukemia mice
developed from MLL-AF9-transduced Hsf1ﬂ/ﬂ HSPCs (duplicate per
genotype), respectively. cDNA synthesis and ampliﬁcation were performed using the SMARTer Ultra Low Input RNA Kit (Clontech) starting
with 20 ng of total RNA per sample, following the manufacturer’s
instructions. cDNA was fragmented with Q800R sonicator (Qsonica)
and used as input for NEBNext Ultra DNA Library Preparation Kit (NEB).
Libraries were sequenced on Illumina’s HiSeq2000 in single-read
mode with a read length of 50 nucleotides producing 60–70 million
reads per sample. Sequence data in fastq format were generated using
the CASAVA 1.8.2 processing pipeline from Illumina. Differential
expression analysis was performed using the DESeq2 v1.30.1 R
package97. We considered genes differentially expressed between 2
groups of samples when the DESeq2 analysis resulted in an adjusted pvalue of <0.01 and the log2-fold change in gene expression greater
than or equal to 1.5 or less than or equal to −1.5. Gene set enrichment
analysis (GSEA) 3.0 was done according to the previous report using
the software downloaded from GSEA website (http://software.
broadinstitute.org)98.

Data analysis
Acquired GC-MS data were processed by Thermo Scientiﬁc TraceFinder 4.1 software, and metabolites were identiﬁed based on the
University of Iowa Metabolomics Core facility standard-conﬁrmed, inhouse library. NOREVA was used for signal drift correction94. Data were
normalized to total ion signals and MetaboAnalyst 4.0 was used for
further statistical processing and visualization95. Natural abundance
and isotopologue distributions were calculated, as previously
described96.

Immunohistochemistry and evaluation of HSF1 expression by
digital image analysis
A 4-year retrospective search from Oct. 1, 2015, to July 2, 2019, of BM
biopsies with AML diagnoses was performed. The electronic medical
record was reviewed for each patient and cases were selected at the
following time points: diagnosis, post therapy, remission, and relapse.
The HSF1 immunohistochemical staining of archived human AML tissue blocks was performed at the University of Iowa under protocol
“The role of HSF1 in regulating hematopoietic and leukemic stem cells
(IRB # 201903742)”. Unstained BM biopsy or clot section slides from
patients with AML at diagnosis, remission and relapse or negative
lymphoma staging BM or clot section samples (controls) were used for
HSF1 (Invitrogen, Cat#MA5-27688, 1:1000 dilution) and/or CD34
(Dako, Cat#M7165, 1:100 dilution) immunohistochemical staining
using standard protocols. Brieﬂy, tissue sections were deparafﬁnized
in xylene and rehydrated in graded alcohols. Endogenous peroxidase
was blocked with 3% hydrogen peroxide followed by antigen retrieval.
Primary and secondary antibodies were incubated for 60 and 30 min,
respectively, at room temperature. After wash, Vectastain ABC reagent
was applied, followed by Dako DAB Plus (5 min at RT), Dako DAB
Enhancer (3 min at RT) and counterstained with Leica/Surgipath
Hematoxylin (1 min at RT). HSF1 immunostained-slides were scanned
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Cleavage under targets & release using nuclease (CUT&RUN)
experiments
CUT&RUN was performed using a CUT&RUN Assay Kit (Cell Signaling
Technology #86652). Brieﬂy, 80,000 cells were washed in Wash Buffer
and bound to 10 μl of activated Concanavalin A beads. Bead-bound
cells were incubated with primary antibodies at 4 °C overnight in
antibody binding buffer. HSF1 (ENZO, Cat# ADI-SPA-901-F), αH3K4me3 (Cell Signaling Technology, Cat#C42D8), and Rabbit IgG
(Cell Signaling Technology, Cat#DA1E) primary antibodies were used.
Then, the cell-bead mixture was washed with Wash Buffer and incubated with Protein A-MNase for 1 h at 4 °C. After washing with Wash
Buffer, 2 mM CaCl2 was added to the samples to activate Protein
A-MNase digestion for 30 min on ice. The reaction was stopped with
the addition of 2x Stop Buffer containing 20 mM EDTA, 0.05% digitonin, 5 mg/ml RNase A, and 2 pg/ml heterologous spike-in DNA.
Released chromatin fragments were puriﬁed by DNA Puriﬁcation
Buffers and Spin Columns (Cell Signaling Technology, #14209).
Libraries were generated using the SMARTer ThruPLEX DNA-seq Kit
(TAKARA) and sequenced on the Illumina’s HiSeq2000.

Bone marrow (BM) transplant experiments
For BM transplantation (BMT), sorted lin−kit+Sca1+ cells (2500 cells/
recipient, 6 recipients per genotype) from Hsf1ﬂ/ﬂ or Hsf1ﬂﬂVavCre+
mice along with 2–3 × 105 radioprotective CD45.1 whole BM cells were
injected into retro-orbital venous sinuses of lethally irradiated
CD45.1 recipients. In our experience, both retro-orbital and tail vein
injection work equally well for normal HSPC transplantation. For
leukemia cell transplantation (see below), we used tail vein injection
to avoid the occasional localized tumor formation in the orbital
region caused by the residual AML cells. Beginning 4 weeks after
transplantation and continuing for 16 weeks, blood was obtained
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from recipients, subjected to ammonium-chloride potassium red cell
lysis, and stained with CD45.2 PECy7 and CD45.1 APC along with B220
BV421 and CD3 PE, Mac-1 FITC and Gr1 PECy5 for monitoring donor
engraftment and donor-derived lymphoid and myeloid cells. Successful engraftment was deﬁned as the presence of a distinct
CD45.2+CD45.1− population above a background set by parallel analyses of animals transplanted with only competitor cells. For secondary and tertiary transplantation, 3 × 106 WBM cells from the
primary or secondary transplants were injected into lethally irradiated congenic CD45.1 recipients, respectively.
For human HSPC transplantation, sublethally irradiated NSGS
mice (Jackson Laboratories, stock# 013062) were injected with
human BM CD34+ HSPCs transduced with pL-CRISPR.EFS.GFP or pLCRISPR.HSF1.EFS.GFP (knockout HSF1) via tail vein in a ﬁnal volume
of 0.2 ml of PBS with 0.5% FBS. Eight weeks later, recipient mice were
sacriﬁced to analyze the engraftment of donor cells.
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Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The RNA-seq and CUT&RUN data reported in this paper have been
deposited in the National Center for Biotechnology Information’s
Sequence Read Archive (SRA) database with the BioProject ID:
PRJNA782637. All the other data are available within the article and
its Supplementary Information. The raw numbers for charts and
graphs and the uncropped blots are available in the Source Data ﬁle.
Source data are provided with this paper.
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